Broncus Holding Corporation (HKG:2216)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.410
+0.040 (2.92%)
Mar 10, 2026, 3:58 PM HKT
93.15%
Market Cap 722.10M
Revenue (ttm) 47.72M
Net Income (ttm) -118.94M
Shares Out 527.08M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 779,000
Average Volume 463,825
Open 1.370
Previous Close 1.370
Day's Range 1.340 - 1.440
52-Week Range 0.700 - 3.720
Beta 1.12
RSI 20.87
Earnings Date Mar 27, 2026

About Broncus Holding

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of COPD; H-Marker, a pulmonary surgical marker can be used... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2012
Employees 171
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2216
Full Company Profile

Financial Performance

In 2024, Broncus Holding's revenue was $8.13 million, a decrease of -20.71% compared to the previous year's $10.26 million. Losses were -$15.30 million, -45.52% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.